PD30 - Management of pediatric anaphylaxis - comparison between a district general hospital (DGH) and a regional centre in UK
© Jyothi et al; licensee BioMed Central Ltd. 2014
Published: 28 February 2014
Anaphylaxis is a serious, life-threatening hypersensitivity reaction. The incidence of anaphylaxis is 4-5 per 100,000 persons per year and is reported to be increasing in recent years.
We analysed management of suspected anaphylaxis in children at a DGH and a regional referral center in UK.
A retrospective case note analysis was carried out between January 2007 and September 2012, which was compared to NICE (National Institute of Clinical Excellence) guidelines.
Percentage of children who received intervention (%)
Adrenaline IM(pre-hospital + in hospital)
Compliance with NICE guidelines on discharge
Percentage of children (%)
Allergy clinic follow up planned
Issued with adrenaline auto injector
Documented training in auto injector use if given
Patients receiving discharge information about anaphylaxis
Patients receiving discharge information fulfilling the criteria stated by NICE
Both centers’ were good at documenting acute clinical features (>95%) and the circumstances prior to symptom onset (>93%). Both hospitals need to improve their documentation of time of onset of reaction (50:30%), informing about biphasic reaction (8.5- 1%) and supply information regarding support groups (1.4-0%). Our study revealed no child received full discharge information according to NICE criteria.
The DGH performed better than the tertiary center in referral to specialist allergy services providing adrenaline auto injector and demonstration of auto injector.
The DGH outperformed the tertiary center likely due to availability of specialist allergy services. We endeavor to improve our management by establishment of specialist allergy services at the tertiary hospital and anaphylaxis education among all doctors.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.